{"id":"W4407081872","doi":"10.1158/2767-9764.crc-24-0601","title":"Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; F. Hoffmann-La Roche","keywords":"Pembrolizumab; Metastatic melanoma; Medicine; Oncology; Melanoma; Internal medicine; Immunotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001077623,0.001050675,0.001463109,0.000296982,0.0003185196,0.0007446316,0.0005896155,0.0006545291,0.001867064],"category_scores_gemma":[0.0004751207,0.0004148967,0.000732702,0.0002359949,0.0005935616,0.000444624,0.0002246746,0.002172125,0.0005744874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007764735,"about_ca_system_score_gemma":0.001406185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008794407,"about_ca_topic_score_gemma":0.002031532,"domain_scores_codex":[0.9996217,0.0001779384,0.00002344786,0.00005793349,0.00004766806,0.00007117343],"domain_scores_gemma":[0.9996289,0.00004545168,0.00009649663,0.00002882084,0.00002519554,0.0001751474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4062923,0.1200355,0.01695319,0.001136836,0.001665313,0.0004990947,0.0003997884,0.003571169,0.2813148,0.0003059719,0.002898503,0.1649275],"study_design_scores_gemma":[0.2467209,0.7053559,0.0151209,0.00004998212,0.0005565087,0.0005763228,0.00008091603,0.001600967,0.02634606,0.0001066943,0.003461809,0.00002302793],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959269,0.001279735,0.0004275345,0.0001712294,0.00006760019,0.001025508,0.0002278075,0.00004676208,0.0008268937],"genre_scores_gemma":[0.9957452,0.000772526,0.0009906341,0.000222173,0.0001238869,0.0007525408,0.0005603625,0.00001459085,0.0008180955],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001867064,"threshold_uncertainty_score":0.006245911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1569885752029877,"score_gpt":0.5087172314434762,"score_spread":0.3517286562404885,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}